Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H1 2017

  • ID: 4284824
  • Report
  • 77 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Amgen Inc
  • AstraZeneca Plc
  • Eisai Co Ltd
  • Eli Lilly and Company
  • Genentech Inc
  • MORE
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H1 2017

Summary:

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Beta-secretase 1 (BACE1) is an enzyme that in humans is encoded by the BACE1 gene. It is responsible for the proteolytic processing of the amyloid precursor protein (APP). It cleaves at the N-terminus of the A-beta peptide sequence of APP. This leads to the generation and extracellular release of beta-cleaved soluble APP and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase.

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) pipeline Target constitutes close to 26 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 5, 1, 1 and 12 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 6 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Alzheimer's Disease, Dementia Associated With Alzheimer's Disease, Mild Cognitive Impairment and Neurodegenerative Diseases.

The latest report Beta Secretase 1 - Pipeline Review,, outlays comprehensive information on the Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope:

- The report provides a snapshot of the global therapeutic landscape for Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)
- The report reviews Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)targeted therapeutics and enlists all their major and minor projects
- The report assesses Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics

Reasons to Buy:

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Amgen Inc
  • AstraZeneca Plc
  • Eisai Co Ltd
  • Eli Lilly and Company
  • Genentech Inc
  • MORE
Introduction

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Overview

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Companies Involved in Therapeutics Development

Allergan Plc

Amgen Inc

AstraZeneca Plc

Bristol-Myers Squibb Company

Eisai Co Ltd

Eli Lilly and Company

Genentech Inc

H. Lundbeck A/S

Johnson & Johnson

Merck & Co Inc

Novartis AG

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Drug Profiles

AMG-8718 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVCRI-104P3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVCRI-175P1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZ-4217 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CNP-520 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elenbecestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ER-901356 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNE-892 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-54861911 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanabecestat camsylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LuAF-66432 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-2811376 + LY-3002813 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3202626 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides to Activate miR-188-3p for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit BACE 1 for Alzheimer’s Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit BACE1 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit BACE1 for Alzheimer’s Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Beta Secretase 1 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit APP-Selective BACE Enzyme for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BACE-1 and GSK-3 Beta for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BACE1 for Alzheimer Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BACE1 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Beta Secretase 1 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-070 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

verubecestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTP-36951 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Dormant Products

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Discontinued Products

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Product Development Milestones

Featured News & Press Releases

Mar 29, 2017: Enrollment Commences In Phase III Clinical Study Of Eisai's Bace Inhibitor Elenbecestat In Early Alzheimer's Disease In Japan

Feb 14, 2017: Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer's Disease to Stop for Lack of Efficacy

Dec 12, 2016: Eisai Presents Latest Data On Bace Inhibitor Elenbecestat (E2609) At 9Th Clinical Trials On Alzheimer’s Disease

Nov 18, 2016: U.S. FDA Grants Fast Track Designation For The Development Of Eisai’s Bace Inhibitor E2609 For Early Alzheimer’S Disease

Nov 02, 2016: Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine

Oct 31, 2016: Enrollment Commences In Phase III Clinical Study Of Eisai's Bace Inhibitor E2609 In Early Alzheimer's Disease

Aug 22, 2016: Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293, an Investigational Treatment for Early Alzheimer's Disease

Aug 09, 2016: U.S. FDA Confirms Sufficient Data to Advance Investigational Bace Inhibitor E2609 for Treatment of Early Alzheimer’s Disease to Phase III

Jun 14, 2016: New Alzheimers Study Aimed at Preventing or Delaying Symptoms

Apr 08, 2016: AstraZeneca and Eli Lilly and Company announce continuation of pivotal clinical trial for people with early Alzheimer’s disease

Jan 28, 2016: Merck Completes Enrollment in Pivotal Phase 3 “EPOCH” Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimer’s Disease

Dec 01, 2014: AstraZeneca and Eli Lilly and Company initiate pivotal clinical trial for patients with early Alzheimer’s disease

May 07, 2014: AstraZeneca In Discussions For Partnership To Develop Alzheimer's Drug

Dec 10, 2013: Merck Advances Development Program for Investigational Alzheimer’s Disease Therapy, MK-8931

Jul 14, 2013: Merck Presents Findings from Phase 1b Study of Investigational BACE Inhibitor, MK-8931, in Patients with Alzheimer’s Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development by Stage of Development, H1

Number of Products under Development by Therapy Areas, H1

Number of Products under Development by Indication, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Investigation by Universities/Institutes, H1

Products under Investigation by Universities/Institutes, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Pipeline by Allergan Plc, H1

Pipeline by Amgen Inc, H1

Pipeline by AstraZeneca Plc, H1

Pipeline by Bristol-Myers Squibb Company, H1

Pipeline by Eisai Co Ltd, H1

Pipeline by Eli Lilly and Company, H1

Pipeline by Genentech Inc, H1

Pipeline by H. Lundbeck A/S, H1

Pipeline by Johnson & Johnson, H1

Pipeline by Merck & Co Inc, H1

Pipeline by Novartis AG, H1

Dormant Projects, H1

Discontinued Products, H1

List of Figures:

Number of Products under Development by Stage of Development, H1

Number of Products under Development by ndications, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Allergan Plc
  • Amgen Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Eisai Co Ltd
  • Eli Lilly and Company
  • Genentech Inc
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Merck & Co Inc
  • Novartis AG
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll